key: cord-0066285-tqqn2txa
authors: nan
title: Abstract
date: 2021-07-29
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12554
sha: 1fccc5f9f2ad25c7efcae55a07249b0ca84b133d
doc_id: 66285
cord_uid: tqqn2txa

nan

use beyond the research setting has lagged. During a 4-cycle quality improvement project, our academic pediatric hemostasis group developed and optimized the use of an electronic version among faculty and trainees. Because scores trend lower in younger children, a tool was created as a flowsheet in the electronic medical record that scores the PBQ plus 2 family history questions (HemPBQ). The questions, responses and scores are added to clinic notes as a "dot phrase."

Objectives: For the 13 months after HemPBQ flowsheet build, we evaluated its use by 5 academic providers and their trainees in the pediatric Hemostasis group for new possible bleeding disorder clinic visits and studied patient demographic and clinical information. Hypothesis: Use of a bleeding assessment tool (HemPBQ) in the electronic medical record will be sustainable one year following its implementation.

Methods: After IRB approval, records from all new clinic visits scheduled as "possible bleeding disorder" from January 29, 2019 through February 28, 2020 were retrospectively reviewed for clinical and demographic data and for the presence of the HemPBQ in the electronic clinic note (EPIC © 2020 Epic Systems Corporation).

Data are reported descriptively.

Results: Over 13 months, for 313 visits, 98.7% had a HemPBQ assessment in the clinic note. Females constituted 60% of patients, with a mean age of 4 years (4-15 IQR). The most common referral indication was for abnormal lab results (Table 1) . Clinician-initiated documentation of screening for joint hypermobility by examination or history-taking occurred in 86 visits (27.5%).

Conclusions: Use of standardized bleeding history questions can provide consistency, speed documentation and serve as an educational tool for trainees. When available as a flowsheet in the electronic medical record, use of the PBQ with family history questions remained extremely high (98.7%) for new patient visits seen by 5 academic providers and their trainees, even a year after its introduction. By contrast, provider-initiated documentation of screening for joint hypermobility was much less frequent. Future data analysis will look at the positive and negative predictive value of the HemPBQ for a bleeding disorder in new pediatric hematology clinic patients. using the IPF % as a predictive tool for platelet transfusion response in adult cancer patients.

We conducted a prospective pilot study in 47 cancer patients with mild to severe thrombocytopenia. Blood samples were obtained before and after transfusion to measure the corrected count increment (CCI). Aliquots of each aphaeresis were obtained from the blood bank services to determine IPF % and P selection expression by flow cytometry.

There is no correlation between IPF % of the platelet bag and CCI (p = 0.14782632; Figure 1 , Table 1 ). All other variables were analyzed to see if there were any other variables that may have correlated with CCI. As a result, we determined aphaeresis product platelet count/ unit volume was correlated with CCI (p = 0.0361/0.0145; Table 1 ). Results: A total of 209 patient records were screened. 104 patients were eligible and included in the study. Majority of patients (83.6%) of patients had a line associated clot. Two-third of patients (n = 66, 63.5%) received therapeutic anti-coagulation while 34.6% were observed. The rate of complication from treatment occurred in 25% of the entire cohort, 10% of which were bleeding complications in patients receiving anti-coagulation (Table 1) . There was no difference in the odds of complete resolution between patients who were treated with therapeutic anti-coagulation and those that were observed (OR 1.07, 95% CI 0.44-2.6, p-value 0.88). Removal of line made no difference in outcome (OR 1.4, . Presence of maternal pre-eclampsia (OR 0.17, 95% CI 0.03-0.89, p-value 0.04) and maternal chronic hypertension (OR 0.12, 95% CI 0.02-0.6, p-value 0.01) was associated with a reduced odds of complete resolution of the clot. Patients that were large for gestational age also tended to have reduced odds of clot resolution. (OR 0.21, 95% CI 0.04-1.15, p-value 0.07). Conversely, patients with history of necrotizing enterocolitis had an increased odds of clot resolution (OR 7.8, 95% CI 1.0-63.2, p-value 0.05) ( Table 2) . Conclusions: The short-term outcome of neonatal VTE does not seem to differ between those that were treated with medications and those that were observed with serial imaging. Additionally, conditions that cause uteroplacental insufficiency like pre-eclampsia and chronic hypertension may be associated with increased morbidity for neonatal VTE. torical AAR: 9.0), a 77% reduction in mean AAR was observed with givosiran treatment vs. pbo in the DB period (Table 1) . A similar reduction (63%) in mean AAR was observed in those without prior hemin prophylaxis (median historical AAR: 7.0). In both groups, further reduction in AAR was observed in patients who continued on givosiran in the OLE period (Table 1) . A similar reduction in AAR was observed in both groups of pbo patients who received givosiran in the OLE ( Table 1 ). The percentage of patients with 0 composite attacks increased in each group following 6-months of givosiran treatment in the OLE with 55% and 67% in the patients who had continued givosiran treatment (Table 1) . Additional outcomes measures will be presented. Conclusions: Clinically meaningful reduction in the AAR was observed in AHP patients treated with givosiran regardless of whether they received hemin prophylaxis prior to study entry, with further AAR reduction observed in those who continued receiving givosiran during the OLE. In addition, a similar benefit was observed in pbo patients who received givosiran for 6-months during the OLE period regardless of prior hemin prophylaxis use Other: This submission is being presented to inform hematologists, who are the most frequent primary treater type for acute hepatic porphyia. Specifically, the study reports the results on those patients were required to stop IV hemin prophylaxis in order to enter the ENVISION trial where givosiran was evaluated. Hematologists are frequently the central provider deciding when to initiate IV hemin and how to manage side effects/toxicities during chronic administration. Thus this data is germane to the hematology community. clophosphamide in one patient, and more complex prolonged treatment in three. Three of six relapsing patients received corticosteroid monotherapy, two received corticosteroid/rituximab, and one was treated with corticosteroid/cyclophosphamide/therapeutic plasma exchange (TPE) at an outside center. The number of relapses ranged from one to three with follow up durations of 68 days to 23.4 years.

Combination therapy with corticosteroid/rituximab was used as treatment of first relapse in five out of six patients and all three patients in second relapse. Remissions ranged from 42 days to 20 years ( Figure 1 ). Median remission after initial treatment was 267 days while median remission after treatment of relapse was 905 days.

Two patients eventually required maintenance therapy with mycophenolate mofetil. Rituximab 375 mg/m 2 IV once weekly for four weeks was most frequently used; however, multiple patients were treated with additional doses in an episode, or retreated on subsequent episodes, resulting in durable remissions. Treatment related toxicities were most common with corticosteroids and included infection, hyperglycemia, cytopenia, and psychiatric syndromes. Creek, California, USA; 4 Haemnet, London, England, United Kingdom; 5 Imperial College London, London, England, United Kingdom; 6 Irish Haemophilia Society, Dublin, Ireland; 7 Barts and The London School of Medicine and Dentistry, London, England, United Kingdom; 8 Institute for Policy Advancement Ltd., Washington DC, District of Columbia, USA Background: Severe hemophilia is characterized by spontaneous hemarthrosis leading to progressive joint deterioration and chronic pain. Unless these recurrent hemarthroses can be prevented, patients will develop chronic synovitis, pain, and destruction of the joint. Metrics such as 'Target joint' and other clinical measures of joint morbidity are prevalent and widely accepted, though measures focused solely on bleeding activity, are arguably becoming less sensitive as current treatment strategies look to reduce or eradicate hemarthroses. They continue, however, to remain clinically relevant and complementary to delivery of comprehensive hemophilia care.

'Problem Joint' (PJ), defined as having chronic joint pain and/or limited range of movement due to chronic synovitis and/or haemophilic arthropathy, with or without persistent bleeding was derived through consensus of key opinion leaders in the haemophilia field.

Objectives: Initial research presented here was used to test the sensitivity of PJ as a patient relevant metric with respect to key outcomes for US hemophilia patients.

Methods: Data on PJs, as well as demographic, clinical and socioeconomic variables was captured within the 'Cost of Haemophilia:

A Socioeconomic Survey' a family of datasets containing over 4,000 people with hemophilia (PwH). The US adult cohort (CHESS US+) comprised the focus of this piece. Statistical analysis explored the association of PJ count and location with respect to quality of life (EQ-5D score), and overall work impairment, measured by the Work Productivity and Activity Impairment Questionnaire. Patients with current inhibitors were excluded from the analysis. 

Background: In recent years, it has been increasingly recognized that hemophilia carriers manifest a wide range of coagulation factor levels and may have bleeding tendencies even at coagulation factor levels that are within the normal range Objectives: To evaluate bleeding symptoms in hemophilia A and B carriers using the ISTH Bleeding Assessment Tool (BAT) and to determine associations between coagulation factor levels and bleeding symptoms.

Methods: A retrospective chart review of hemophilia carriers seen at the Utah Center for Bleeding and Clotting Disorders from 2004 to 2020 was conducted. The following data were extracted: Hemophilia type, baseline factor levels, age at time of clinic visit, race/ethnicity, body mass index (BMI), family history, genetic testing (if available) and ISTH BAT scoring/characteristic symptoms. Descriptive statistics were used in the analysis.

Results: 46 hemophilia carriers were included in this study (hemophilia A, n = 27, hemophilia B n = 19) . Characteristics of the cohort and the bleeding symptoms reported by the cohort are shown in Table 1 . In our cohort, hemophilia carriers with high BAT score ≥6 showed a median factor level of 38 IU/dL (IQR: 25%), while hemophilia carriers with BAT score < 6 had a median factor level of 39 IU/ dL (IQR: 50%). As such, hemophilia carriers need equal attention and standard of care similar to their male counterparts. Our review of the data suggests poor discrimination of using BAT score with median factor levels, which highlights that BAT score might be more useful to predict risk of bleeding than baseline factor levels. Methods: Total IgG was purified from HA patient plasma using a protein G spin column. Subsequently, anti-FVIII antibodies were isolated from the total IgG pool using biotinylated full-length FVIII (FVIII-SS-biotin) immobilized to magnetic streptavidin beads. FVIII-SS-biotin was produced using an optimized biotinylation procedure yielding <15 attached biotins per FVIII molecule. At this degree of biotinylation, there was only minimal reductions in FVIII specific activity, as determined by a one-stage plasma-based assay, and monoclonal antibody binding, as determined by ELISA.

Complete elution of FVIII-bound IgG was achieved by reducing the disulfide biotin linkage. Both eluted IgG and IgG in the flow-through were analyzed by LC-MS/MS, and label-free quantification was performed in MaxQuant using the patient's B cell receptor library as the sequence database. Anti-FVIII antibodies were defined as those present in both replicates of the elution with >100-fold greater intensity than in the flow-through.

Results: FVIII-SS-biotin was able to fully capture a panel of 12 monoclonal antibodies, targeting all five immunogenic domains of FVIII, spiked into normal human plasma. Monoclonal antibodies were identified in LC-MS/MS spectra at concentrations as low as 10-100 fmol in the input. This is comparable to the sensitivity of LC-MS/MS, highlighting that our anti-FVIII IgG purification protocol does not limit the sensitivity of this approach.

In this study, we performed two replicate purifications from two time points of a pediatric HA patient with a high-titer inhibitor. We achieved ≥97% capture of anti-FVIII IgG by ELISA and complete capture of inhibitors by Bethesda assay for all replicates. Concurrently, 3-4 × 10 7 PBMCs from each time point were processed for highthroughput B cell receptor sequencing. Collection and analysis of these results is ongoing.

We developed a novel and efficient strategy to isolate anti-FVIII antibodies without epitope bias from HA inhibitor patients with a sensitivity sufficient for downstream immunoproteomic studies. Combining these results with ongoing paired B cell receptor sequencing will provide valuable insight into the development of the human anti-FVIII immune response. cardiac support in patients with cardiac failure has increased in the recent years due to increasing clinical experience and technological advances. ECMO is invasive and associated with serious complications, including severe hemorrhage; bleeding. The initiation and maintenance of ECMO require significant blood product support. In these critically ill patients, the increased risk for hemorrhagic complications increases the need for blood product administration.

We conducted a quality improvement (QI) project to look into the blood product utilization and anticoagulation practice within 24 hours of ECMO cannulation between pre-intervention phase (2017-mid 2018) before our recommendations and postintervention phase (mid-2018 to 2019) after the implementation of the recommendations. The aim of this QI project was to evaluate the factors that affect bleeding in patients on ECMO and reduce blood product utilization during the first 24 hours after ECMO cannulation.

A single-center QI project 15 months pre intervention phase post intervention phase of blood product usage in the first 24 hours after ECMO cannulation and anticoagulation. Based on our evaluation, we recommended to decrease heparin dose during cannulation and to follow trauma massive transfusion protocol if there is increased bleeding. Data from the subsequent 15 months were collected and evaluated. The study comprised of 40 patients in total.

The blood product utilization was compared pre and post recommendations using Wilcoxon rank-sum test and negative binomial regression adjusting for patients' characteristics and clinical variables.

Results: After adjusting for the patient's characteristics and clinical variables, the FFP (p = 0.0003), PRBC (p < 0.0001), platelets (p < 0.0001), and Cryoprecipitate (p = 0.0003) usage in the postintervention phase are statistically significantly lower than those in pre-intervention phase. The post-intervention (Mean ± SD) heparin dose (in units) during the cannulation (8812.5 ± 7382.1) was lower than pre-intervention dose of heparin (17357.1 ± 15648.1) p = 0.066. Twenty percent of patients in pre phase had Veno-Venous extracorporeal membrane oxygenation (VV-ECMO), whereas 68% of patients in the post-phase had VV-ECMO, p = 0.005. VV-ECMO patients received fewer packed red cells in (Mean ± SD) (6 ± 15.7 v 19.3 ± 22.13 Units per 24 hours p = 0.011) and platelets (3.4 ± 12.7 v 4.6 ± 5.7 Units per 24 hours p = 0.035) compared with Veno-Arterial extracorporeal membrane oxygenation (VA-ECMO); patients.

Conclusions: Following our recommendations, the blood product utilization(pRBC, FFP, platelets, and cryoprecipitate) in the first 24 hours was decreased compared to the baseline, which was statistically significant. Heparin utilization during the time of canulation was lower following our recommendations. The overall usage of blood products was low in VV ECMO patients compared to VA ECMO patients. Objectives: In this study, we investigate human EC production of the components of the prothrombinase complex (FX, FV, and prothrombin [FII] ), and the generation of thrombin by cleavage from prothrombin of fragment 1+2 (F1+2).

Human umbilical vein ECs (HUVECs), glomerular microvascular ECs (GMVECs), and liver sinusoidal ECs (LSECs) were grown to confluence in serum-containing media. For protein quantification assays, ECs were washed and exposed to serum-free media for 24 hours. Supernatants were collected and lysates were made (following additional washing) for analysis using a commercial ELISA kit for FV. For F1+2 measurements (also using a commercial ELISA kit) 5 mM CaCl 2 was added to the serum-free media. Fluorescent microscopy, combined with antibodies directed against human FII/ thrombin and CD141 plus appropriate fluorescently-tagged secondary antibodies, was used to detect these proteins on ECs grown on glass coverslips. Image analysis was utilized to determine if FII/ thrombin detection overlapped with the fluorescent detection of CD141 on cell surfaces.

: FV protein is produced by HUVECs, GMVECs, and LSECs; and detected in the supernatant and lysates of each EC type (Figure 1a, b) . Similar levels of FV were detected in the three EC supernatants (n = 3 for each cell type), although HUVEC lysates (n = 2) contained more FV than GMVECs (n = 3) and LSECs (n = 3, p < 0.0001), and LSECs contained more FV than GMVECs (p = 0.03).

Fluorescent image analysis demonstrated colocalization of prothrombin (FII)/thrombin with CD141 on HUVEC surfaces ( Figure 2 ).

The prothrombin cleavage product, F1+2, was not detected in EC supernatant, although it was measured in EC lysates (Figure 1c ). This may indicate surface binding of F1+2 following prothrombin cleavage. GMVECs produced more F1+2 than HUVECs (p = 0.03) and

LSECs.

Conclusions: In addition to producing the coagulation proteins necessary for FX activation, human ECs also produce FV and prothrombin. We provide evidence of active prothrombinase formation with cleavage of F1+2 fragments from prothrombin cleavage detected in EC lysates. Our data provide additional evidence that human ECs may have important roles in promoting hemostasis, in addition to their anticoagulant properties. Background: Blood platelets are critical for the prevention of bleeding following vascular injury. Key to their function is the activation of cell surface integrin receptors, a process that is regulated by a powerful yet tightly controlled intracellular signaling machinery. Following cellular stimulation and second messenger generation, the small GTPase Rap1 plays a central role in the assembly of the integrin activation complex. Rap1 itself cycles between an inactive, GDP-bound and an active, GTP bound state. Rap1 activation and inactivation are mediated by CalDAG-GEFI, a calcium-sensitive guanine nucleotide exchange factor (GEF), and Rasa3, a GTPase activating protein (GAP), respectively. Once activated, Rap1 interacts with talin to mediate integrin activation. While the components of the Rap1-integrin signaling module are well defined in platelets, these cells are ill-suited for detailed studies on the spatiotemporal regulation of the pathway.

Objectives: To utilize immortalized megakaryocytic cells (imMKCLs) as a surrogate model for studying the spatiotemporal regulation of platelet Rap1-integrin signaling.

Methods: Protein expression of CalDAG-GEFI, Rasa3, Rap1 and talin was assessed in imMKCLs by Western blot. Integrin activation was monitored by flow cytometry (PAC1 binding) and confocal microscopy (fibrinogen binding). Lentiviral vectors are used to express wildtype and mutant forms of CalDAG-GEFI and Rasa3 in imMKCLs.

Expression of the components of the Rap1-talin signaling module was determined in imMKCLs during a 7-day differentiation and in platelets derived from these cells. The expression of Rasa3 and talin did not change during imMKCL differentiation. In contrast, Rap1 expression increased over time and was highest in d7 imMK-CLs. Expression of CalDAG-GEFI was very low in d1-6 imMKCLs and increased strongly in d7 imMKCLs and imMKCL-derived platelets.

PAC-1 binding was determined after agonist stimulation at different stages of MK differentiation. A subset of d5 imMKCLs showed robust PAC1 binding in response to protease-activated receptor (PAR) or glycoprotein (GP)VI stimulation. Single cell confocal microscopy studies demonstrated that fibrinogen binding in activated imMKCLs is observed in cells that mount a strong second messenger (calcium flux) response. However, the kinetics of calcium flux did not correlate well with the kinetics of fibrinogen binding in stimulated d5 imMKCLs, Patients receiving on-demand treatment or prophylaxis (PPX, 30-40 IU/kg twice weekly [2×W], 45-60 IU/kg every 5 days [E5D], or 60 IU/kg every 7 days [E7D]) with damoctocog alfa pegol in the main study could continue their regimen or switch to any PROTECT VIII PPX regimen at any time during the extension. PPX patients who switched regimen after the first 7 days in the extension were assessed in a variable frequency group (VAR). All patients were assessed for annualized bleeding rate (ABR), joint ABR and safety outcomes. Bleeds and damoctocog alfa pegol treatments were reported in an electronic patient diary.

Results: At enrollment, 12 patients were aged 12 to less than 18 yrs and are included in this analysis; all but one were previously treated with PPX. Ten out of 12 patients had at least one investigatorreported target joint at baseline: 5 patients had target joints in ankles, 4 in elbows and 2 in knees; 3 patients had >1 target joint. Median (range) age was 13.5 (12-17) yrs at enrollment and approximately 18 (15-23) yrs at the end of the extension. All patients completed the 36-week main study and enrolled into the extension; total time in the full study ranged 1.28-6.17 yrs. During extension, patients were treated with damoctocog alfa pegol PPX (2×W, n = 3; E5D, n = 3; E7D, n = 2; VAR, n = 4); median (Q1; Q3) annual dose was 3885 (3243-4200) IU/kg and median (range) number of infusions/ yr was 81 (54-108). Total and joint ABRs for each time period are shown in Figure 1 . During the last 12 months of the extension, all target joints present at pre-study (as reported by the investigator) or that developed during the study (3 bleeds into the same joint in 6 months), were resolved (≤2 spontaneous bleeds/yr). Drug-related treatment-emergent adverse events (TEAEs) were reported in 1 patient (osteoarthritis, moderate intensity). While 4 patients were reported to have had serious AEs at the end of PROTECT VIII extension (Table 1) , none were study drug-related. No patients developed FVIII inhibitors during the entire study (titer ≥0.6 Bethesda units). Results: Jak2Plt-/-mice developed MK hyperplasia and splenomegaly associated with severe thrombocytosis and bleeding. This notion is supported by failure to occlude in a ferric chloride carotid artery injury model and by a cremaster muscle laser induced injury assay, where Jak2Plt-/-platelets failed to form stable thrombi. Jak2Plt-/platelets adhered poorly to type I collagen under arterial shear rates.

Jak2Plt-/-platelets also spread poorly on collagen under static conditions or on fibrinogen in response to the GPVI-specific agonist, collagen-related peptide (CRP). Following activation with CRP, Jak2Plt-/-platelets displayed decreased α-granule secretion, integrin αIIbβ3 activation, and aggregation, but showed normal responses to thrombin. Jak2Plt-/-platelets had impaired intracellular signaling when activated via GPVI as assessed by phosphotyrosine expression, which was associated with abrogated phosphorylation and activation of PLC-γ2. Objectives: Establishing a better understanding of the surgical process and current unmet needs may provide better awareness and support for persons with hemophilia.

Methods: Through a combination of virtual and live sessions, health care providers (HCPs), including nurses, physicians, pharmacists, physical therapists, and social workers, shared insights on the surgical process, educational needs, and future of surgery in patients with hemophilia. Transcripts from these meetings were analyzed to compile qualitative data sets.

Overall, 61 HCPs from 15 states across the United States participated in 1 of 6 virtual or 3 live roundtable discussions. Most of these HCPs were associated with hemophilia treatment centeraffiliated hospitals. Each center averaged 2 surgical procedures per month, most frequently dental procedures and mediport placements or removals. Most HCPs reported having a preferred referral network for surgical procedures; however, patients often elected to have surgery outside of the referral network owing to insurance or personal preference. The largest gaps identified in the surgical process included issues with rehabilitation, communication, and insurance networks (Table 1) . HCPs reported that insurance providers often dictated where physical therapy occurred as well as the duration of physical therapy. HCPs also reported on the educational needs surrounding surgical procedures in patients with hemophilia.

The general consensus was that a diverse group of non-hemophilia treatment center HCPs could benefit from additional education about hemophilia and other rare bleeding disorders. This group included emergency department staff, inpatient and surgical nursing staff, obestetricians/gynecologists, pharmacists, emergency medical technicians, first responders, and intensive care unit staff. Eptacog beta* (EB; HEMA Biologics) is a recombinant activated human factor VII variant that provides effective treatment of bleeding in hemophilia A or B patients with inhibitors, and was approved for use in adults and adolescents (age ≥ 12) by the FDA in 2020.

The study objective is to assess EB safety, immunogenicity, and thrombotic potential during bleed treatment and perioperative care in pediatric and adult hemophilia A or B patients with inhibitors who were enrolled in three prospective Phase 3 clinical trials (PERSEPT 1, PERSEPT 2, and PERSEPT 3).

Methods: Using a randomized crossover design, 27 subjects in PERSEPT 1 (ages 12-54) and 25 subjects in PERSEPT 2 (ages 1-11) treated bleeding episodes with an initial dose of 75 or 225 µg/kg EB followed by dosing of 75 µg/kg at prespecified intervals as determined by clinical response. Twelve PERSEPT 3 subjects (ages 2-56) received an initial pre-operative infusion of 75 µg/kg (for minor procedures) or 200 µg/kg EB (for major surgeries) with subsequent 75 µg/kg doses of EB given intraoperatively and postoperatively as indicated. Two subjects from PERSEPT 1 and two subjects from PERSEPT 2 also participated in PERSEPT 3. Histories of thrombosis, thromboembolism, or risk factors for thrombosis were exclusionary criteria. All subjects (or their parents or legal guardians if <18 years of age) gave informed consent. Descriptive statistics were used for data analyses.

Results: Over the three trials, 60 hemophilia A or B subjects with inhibitors received 3,388 doses of EB during 1,087 exposure episodes (bleeding episodes, invasive procedures, postoperative treatments, and EB pharmacokinetic assessments). EB was well-tolerated, and no allergic, hypersensitivity, anaphylactic, or thrombotic events occurred. No neutralizing anti-EB antibodies were detected. Of 133 adverse events (AEs) that occurred following initial EB exposure, 10 were considered treatment-related and 7 were serious (SAEs; Table 1 ). Following a major surgery that proceeded without complications, one PERSEPT 3 subject was discontinued from the trial due to post-procedural hematoma. This patient succumbed from blood loss anemia approximately 3 days after study withdrawal; the death was found to be unrelated to EB treatment by the independent PERSEPT 3 data monitoring committee (DMC). No SAE was deemed treatment-related by the DMC. Objectives: Here, we assess the seroprevalence of pre-existing neutralizing antibodies (NAbs) and anti-drug antibodies (ADA) against AAVhu37 in humans. Updated long-term safety data following a single dose of the gene therapy, AAVhu37.hFVIIIco, in a first-in-human, Phase 1/2 dose-finding study (NCT03588299) are also reported.

Methods: Seroprevalence of NAbs and ADAs against AAVhu37 were assessed in serum derived from 100 US patients with hemophilia A.

In addition, NAbs against AAV5 and AAV8 were determined. The Phase 1/2, open-label, dose-finding study included male patients aged ≥18 years with severe hemophilia A, receiving a single intravenous infusion of AAVhu37.hFVIIIco. Patients had no history of FVIII inhibitors, no detectable immunity to the AAVhu37 capsid above a titer of 5 and ≥150 exposure days to FVIII products. Primary endpoints were adverse events (AEs), serious AEs (SAEs) and AEs/SAEs of special interest. Secondary endpoint was change in FVIII activity from baseline. Informed patient consent and ethics committee approval were obtained.

In the seroprevalence study, we observed a low seroprevalence of NAbs and ADAs with low maximum titers for NAbs (26) and

ADAs (182) against AAVhu37. Based on our results, 86% of patients would be eligible for AAVhu37-based treatment. To date, patients in Cohorts 1 (0.5 × 1013 GC/kg, n = 2), 2 (1.0 × 1013 GC/kg, n = 2) and 3 (2.0 × 1013 GC/kg, n = 2) have completed up to 21, 16 and 11 months of observation, respectively. Five (83.3%) patients from all three cohorts have shown durable and sustained FVIII levels (all ≥5%). No SAEs have been reported to date. Follow-up data for up to 24 months will be presented.

AAVhu37.hFVIIIco has broad eligibility in patients with hemophilia A due to low seroprevalence of NAbs and ADA against AAVhu37, compared with other AAVs. AAVhu37.hFVIIIco has a good safety profile, and measurable and sustained expression of endogenous FVIII.

Other: All authors are employees of Bayer. transgene, has shown durable FIX expression and low mean annualized bleeding rate/annualized infusion rate up to four years following infusion, representing the longest period of durability data for a FIX Padua-utilizing gene therapy for HB patients to date.

We sought to describe the kinetics of clearance of fidanacogene elaparvovec vector DNA from bodily compartments, following transduction.

Clearance of viral vector DNA was assessed in fifteen adult HB patients who had been infused with 5E+11 vg/kg of fidanacogene elaparvovec, using quantitative real-time PCR (qPCR) analysis of peripheral blood mononuclear cells (PBMCs), saliva, urine, semen, and serum. PBMCs, saliva, urine and serum samples were collected at screening or Day 0 prior to vector infusion, and starting from Week 1 post-vector infusion and continuing at every scheduled visit until 3 consecutive samples were negative (at or below the limit of quantification of the assay) for the given sample type.

Semen samples were collected at Screening or Day 0 prior to vector infusion, and on week 1 and every 4 weeks starting from week 4 post-vector infusion until 3 consecutive samples were negative (i.e., at or below the limit of quantification of the assay). After week 16, semen samples occurred at every scheduled visit (as opposed to every 4 weeks) if 3 consecutive negatives had not yet been obtained.

Time to clearance was defined as time to reach the first negative sample of three negative samples per matrix. Descriptive statistics were used to analyze results for time to clearance and peak viral vector shedding.

Results: All subjects achieved clearance of vector DNA in all specimen types by 52 weeks following vector infusion; semen, urine, and saliva were the quickest to be cleared. All patients had cleared semen by week 12, saliva by week 8, and urine by week 7. Serum and PBMCs were the longest to clear, with serum clearing at week 22 and PBMCs at week 52 following infusion. The peak viral vector shedding in each compartment was observed during the first two weeks after infusion. Among samples with detectable viral vector load, the range was 1.63E+4 to 7.13E+5 copies/mL in saliva, 4.55E+3 to 3.61E+5 copies/mL for semen, 8.96E+2 to 3.57E3 copies/mL for urine, 6.55E+4 to 2.91E+6 copies/mL for serum, and 4.8E+3 to 4.03E+5 copies/ug for PBMCs (Table 1 ). There were no adverse events reported that appeared attributable to systemic vector distribution. Objectives: This quality improvement study aims to implement a risk stratification algorithm for preventing VTE in pediatric patients and ensure appropriate VTE risk stratification and prophylaxis on hospital admission.

Methods: Based on analysis of risk factors and extrapolation of adult empiric data, an algorithm was developed to risk stratify children admitted to our institution. A "hard stop" was inserted into admission ordersets requiring risk stratification. We performed a retrospective chart review of all pediatric patients >10 years old admitted to UCLA hospitals between December 2017 and June 2018, determined whether the risk stratification was done, and compared true risk category with stratification at admission. Based on initial findings, the orderset was updated to clarify the stratification process.

The pediatric history and physical template was updated to require patient ambulatory status and risk factors. A second chart review was conducted for admissions between October 2019 and March 2020.

In the initial review, 552 charts were examined. 97% were risk stratified on admission and 86% were stratified correctly. While 98% of low risk patients were correctly stratified, only 41% of moderate risk patients and 25% of high risk patients were stratified correctly. 67% of incorrectly stratified moderate and high risk patients were non-ambulatory at baseline. After making the above changes, 449 additional charts were examined. 95% were risk stratified and 86% were stratified correctly. 59% of moderate risk patients and 60% of high risk patients were stratified correctly. 41% of incorrectly stratified moderate and high risk patients were non-ambulatory at baseline.

Inserting the "hard stop" into the admission orderset was effective in leading to risk stratification. The vast majority of children were stratified as low risk. Initially, while 86% overall were stratified correctly, the majority of moderate and high risk patients were not, and did not receive appropriate VTE prophylaxis.

Changes made in response led to an increase in correctly stratified moderate and high risk patients, particularly in patients who were non-ambulatory at baseline. Ongoing incorrect stratification in the moderate and high risk groups requires additional attention and will be addressed with further plan-do-study-act cycles. Objectives: 1. To characterize hematology referrals for bleeding disorder work up 2. To describe the diagnostic outcomes from these referrals 3. To estimate the proportion of bleeding disorders diagnosed from these referrals 4. To identify referral factors that are associated with being diagnosed with a bleeding disorder Methods: This is a single center, retrospective chart review. Patients referred and or seen for a bleeding disorder evaluation at Children's Mercy Hospital from 07/1/2018 until 06/30/19 were evaluated for demographics, reason for consultation, referring provider, and referral outcome. Akaike Information Criterion (AIC) was applied to logistic regression to identify factors associated with diagnosis of bleeding disorder.

A total of 373 patients were included with demographics detailed in Table 1 . Forty patients were diagnosed with a bleeding disorder, 78 patients were lost to follow up or had not completed the work up, and 255 patients had a bleeding disorder ruled out. Of our sample, 6% (21/373) were diagnosed with von Willebrand disease, 4% (14/373) with a platelet function disorder, and 1.3% (5/373) with a coagulation factor deficiency. Forty percent of referrals were for preoperative clearance, 36% for family history, and 57% for symptoms. Forty four percent (164/373) of the referrals were from Otolaryngology, 30% from primary care, and 27% from other specialties. The odds of a bleeding disorder diagnosis decreased by 8% for every year increment in age and was 3 times higher among patients having abnormal coagulation labs at the time of referral as compared to their counterpart. Objectives: The objective of this study was to investigate whether PF4 binding to NETs is similarly protective in SARs-CoV-2 infection by preventing the degradation of NETs and by enhancing NETmediated viral capture.

We generated NET-lined microfluidic channels. Neutrophils were isolated from healthy human donors, adhered to fibronectincoated channels, and incubated with phorbol myristate acetate (PMA) to induce the release of NETs. Channels were then treated with buffer alone or PF4 (100 µg/ml) to compact NETs, after which gammairradiated SARS-CoV-2 (1 x 107 PFU) were infused at 2 dynes/cm 2 for 1 hour. Viral particles were then labeled with SARS-CoV-2 guinea pig antiserum and visualized with a fluorescently-labeled secondary antibody. Viral binding to NETs was quantified using confocal microscopy.

Results: Similar to that seen with bacterial attachment to NETs, we observed scant viral binding to non-compact NETs. In contrast, there was abundant binding of SARs-CoV-2 aggregates to PF4 compacted NETs (Figure 2 ). Objectives: There is an unmet need to determine the safety of antiplatelet and anticoagulant medications in PWH to provide better guidance on their management.

A survey was distributed among members of the ADVANCE group, comprised of hemophilia experts from different hemophilia treatment centers (HTC) across the US interested in issues of aging with bleeding disorders, to evaluate their approach to managing PWH while on anti-platelet and anticoagulation agents.

Results: Responses were collected from 7 different HTCs, treating a total of 3503 patients with hemophilia A (HA), B (HB) and carriers. 57 patients older than 45 yo were treated with low dose ASA (81 mg), 2 with dual anti-platelet therapy, and 2 with anticoagulants (warfarin and rivaroxaban) (1.8% of total patients); see Table 1 .

Reasons for ASA use included coronary artery disease, valvular disease, peripheral vascular disease and stroke prevention. ASA dosing regimen varied between daily (70%), every other day (26%) and 3 times/week (4%). Target troughs ranged from 5%-30% and patients were started on prophylaxis or prophylaxis regimen was changed (with increased dose or frequency) by the majority of physicians to achieve higher trough. Most of the patients were treated with standard half-life products. 2 patients with severe HB were switched to extended half-life factor. ASA was stopped in 7 patients (12%) for GI bleed (4), GU bleed (2), and muscular bleed (1) and not resumed after bleed resolution. Bleeds occurred between a week to month after starting ASA. ASA dosing was spaced out in 4 patients due to mucocutaneous bleeds. Difficulties in achieving target was only reported in 2 patients due to adherence problems. Table 1 . Distribution of patients on antiplatelet or anticoagulation therapy by severity and type of hemophilia Conclusions: Some observational studies in non-hemophiliacs treated with low dose ASA suggest around 1-2 major bleeding events (GI and cerebral) / 1000 patients annually. Others suggest 1/210 would experience a serious bleeding event on low dose ASA.

Our data shows that PWH on ASA experience increased risk of GI and other bleeding, with 12% of patients stopping ASA due to bleeding events. A majority of clinicians used or altered factor prophylaxis to achieve a higher trough level, albeit in a non-standardized fashion, to ameliorate the bleeding risk. Limitation of this analysis are the small number and heterogeneity of patients. Our survey results confirm the rarity of antiplatelet and anticoagulation use in this population. Next steps are to expand survey distribution to collect more data in order to optimize the management of antiplatelet and anticoagulation agents in PWH. Objectives: In this study, we sought to study the association between INR and non-variceal hemorrhage in patients with CLD. In addition, we sought to identify additional predictors of non-variceal hemorrhage in CLD.

Methods: This is a large, retrospective cohort study using data Results: A total of 14,384 patients with CLD were included in the cohort of which there were 580 bleeding events (Table 1 ). In multivariate analysis ( A missense mutation(Ser1731Thr) in exon 30 affecting A3 domain has been described in several families with an autosomal dominant inheritance. This mutation leads to an abnormal collagen binding with normal platelet interaction. Previously described cases with this mutation had decreased VWF:CB and normal Rco activity testing.

Objectives: Studying the caveats in the laboratory diagnosis of patients with Type 2 M VWD with missense mutation (Ser1731Thr).

A review of patients with VWD Type 2M carrying the missense mutation(Ser1731Thr) within the Zimmerman cohort.

We report 2 cases of VWD Type 2M. The 1st patient is a 28 years old female, with a history of heavy menstrual bleed and frequent epistaxis. Her family history was positive with a mother and identical twin sister having the same symptoms. She presented for evaluation after her niece was born with a spontaneous intracranial bleed. Her blood work showed vWFAg 67%, vWF:Rco 31% (Rco:Ag ratio 0.46), VWF:CB68% (CB:Ag ratio 1),and GP1bM71%.

GP1bM did not confirm the low VWF:Rco level. Platelet aggregation studies were normal and factor VIII 100%. The 2nd patient is a 9 years old male, he had a history of easy bruising and frequent epistaxis. His blood work didn't show evidence of vWD, with vWFAg 79%, vWF:Rco 75%, (Rco:Ag ratio 0.95), and factor VIII 78%. In both patients, genetic testing showed a missense mutation (Ser1731Thr) in exon 30. Decreased vWF:CB was the mainstay in the diagnosis of patients with vWD type 2M, especially with kits using collagen type I . Our 1st patient had normal vWF:CB(kit used type III collagen),and low Rco ratio with normal GP1bM test. The second patient had normal laboratory evaluation, with strong clinical presentation. Genetic testing was crucial to confirm the diagnosis of vWD type 2M in these patients. to the ER with fever for ≥4 days plus any of the following: GI symptoms, rash, bilateral non-purulent conjunctivitis, cough, headache , and/or irritability. Specialty-specific treatment guidelines, including modifications of an existing VTE prophylaxis guideline, were established (Table 1) . As a quality improvement measure, we performed electronic query of the use of the MIS-C panel including evaluating laboratory trends, and outcomes of cases receiving specific therapeutics, including anticoagulation. We present data regarding hematologic findings and outcomes of VTE prophylaxis in this cohort. (Table 2) . Of these, mild CBC abnormalities predominated as did mild coagulopathy, elevated fibrinogen levels, and d-dimers (on average 5.5 × upper limit of normal) ( Table 2 ). Three (25%) patients met criteria for VTE prophylaxis with enoxaparin which was continued during hospitalization in 1 patient, and for 2 weeks following hospital discharge in the remaining 2. There were no reported thromboses in any patients, including those who did not meet criteria for thromboprophylaxis. Enoxaparin was well tolerated, and no patients had bleeding events despite having mild coagulopathy. Results: Five cases of VTE had various types of clots including pulmonary embolism (PE) and upper or lower extremity DVT (Table 1) and all had one or more antiphospholipid antibody positivity. One Conclusions: Venous thromboembolic disease in children associated with anti-phospholipid antibody is rare but we noted five cases of VTE in association with antiphospholipid antibodies in short period during pandemic, of which one case was associated with SARS-CoV-2 RNA and two cases suggestive of recent infection with SARS-CoV-2 RNA as IgM was positive. We conclude that our case series suggest VTE in children, in association with SARS-CoV-2, is mediated through generation of antiphospholipid antibodies. Further prospective studies can provide clarity on this supposition. (Table 1) . Given her ITP and these serologic markers, a diagnosis of SLE was established (2019 EULAR/ACR classification criteria). She received IVIG and high-dose corticosteroids again, along with 4 weekly doses of rituximab, with no significant improvement in platelet count. Therefore, romiplostim was started, with a rise in platelet count to 103,000/mcL. She was discharged on enoxaparin and a steroid taper. She presented 16 days later with headache, dyspnea, right leg pain, platelet count 33,000/mcL and D-dimer >20,000 ng/mL. Imaging showed a new left transverse and sigmoid CVST, lobar pulmonary emboli and acute thrombus of the right distal common iliac vein. Anti-factor Xa levels were therapeutic.

Antiphospholipid antibodies were again not detected. Malignancy screening was negative. Bone marrow biopsy was unrevealing. The patient was treated with plasmapheresis and high-dose corticosteroids, per the regimen typically used for CAPS. Anticoagulation was switched to argatroban due to concern for enoxaparin failure and was then transitioned to warfarin. D-dimer decreased and platelet count increased to 320,000/mcL. The patient will be starting immu- No deaths occurred; no treatment-related SAEs were reported. 7 pts had infusion-related reactions, 1 infusion was discontinued. 9 pts received steroids for liver enzyme elevations. All discontinued steroids prior to wk26; FIX activity remained in the mild range.

No inhibitors to FIX were reported. No relationship between safety and NAbs was observed.

The first co-primary endpoint was met. Following a single dose of etranacogene dezaparvovec, FIX activity increased, without the need for prophylactic immunosuppression, into the mild-to-normal range at 26 wks in pts with severe/moderately severe HB. Importantly, this included pts with titers of pre-existing anti-AAV5 NAbs. Pts were able to discontinue prophylaxis and bleeding was abolished in the majority. The safety profile was consistent with early phase AAV5 studies and together these data support a favorable safety and efficacy profile for etranacogene dezaparvovec. jncw, EB) is a new rFVIIa manufactured in a transgenic mammalian expression system indicated for the treatment and control of bleeding episodes (BEs) in adults and adolescents (≥12 years) with hemophilia A or B with inhibitors. A phase 3 clinical trial (PERSEPT 2, NCT02448680) in subjects <12 years of age with hemophilia A or B with inhibitors evaluated the efficacy, safety and pharmacokinetics of EB.

Methods: PERSEPT 2 was a global, multicenter, prospective, randomized crossover study of EB (75 and 225 µg/kg) initial dose regimens (IDRs). Male subjects (<12 years) with hemophilia A or B with inhibitors were enrolled. IRB approval was obtained; subjects' legal guardians provided informed consent. Subjects were randomized to one of the IDRs for the treatment of mild/moderate BEs (Figure 1) with crossover to the alternate IDR every 3 months. Efficacy was evaluated at multiple time points for the first 24 h of each BE; the primary efficacy endpoint was at 12 h. Success at each time point was defined as good or excellent hemostasis by the subject/caretaker. In addition, to be considered successful, no additional eptacog beta, alternative hemostatic agent or blood product could be administered (and pain could not increase) following the initial good or excellent assessment and prior to 24 h. [Normal approximation CI taking into account the correlation among bleeding episodes for a given patient]

The clinically meaningful percentage of mild/moderate BEs successfully treated at 12 h (63%), high percentage of BEs resolved at 24 h (98%), low incidence of alternative hemostatic agents use (2%), low occurrence of rebleeding (1.5%), low number of doses required, and absence of treatment-related adverse events observed in the trial demonstrate that eptacog beta provides a new and welltolerated at-home hemostatic agent for the treatment and control of Figure 1 . The 75 µg/kg and 225 µg/kg initial dose regimen (IDR) for treatment of mild/moderate bleeding events in the PERSEPT 2 clinical trial. The initial dose regimens were selected based on PK/ PD modeling from a phase 1b trial; the efficacy of these IDRs was confirmed in the PERSEPT 1 adult/adolescent trial. Additionally, the total amount of eptacog beta administered at the primary efficacy endpoint (12 h) could be the same on both IDRs BEs in individuals younger than 12 years of age with hemophilia A or B with inhibitors. Figure 1B) . Co-incubation with FV also decreased uPA-T uptake, suggesting that both may compete for a common pathway. scuPA and uPA-T studies with von Willebrand Factor (VWF) and with platelet factor 4 showed partial co-localization supporting suggestion that uPA is sorted to a-granules. We asked whether CD34+-MK- conditions of the protocol, be able to provide evidence of previous inhibitor levels, be willing and able to use the ATHN mobile application or a paper diary to document BEs and medication usage, and have read, understood, and documented written informed consent/ assent. The following participant level data will be collected: demographics, bleeding history, medical history including diagnoses and co-morbidities, inhibitor history, clotting factor products(s) and non-factor product(s) treatment plan, concomitant medications, and study drug administration details. In addition, all BEs, surgical procedures and European Haemophilia Safety Surveillance (EUHASS) adverse events will be collected. Participants will be provided with nine 75 μg/kg doses of EB based on the approved initial dose recommendation. Treatment with the approved 225 μg/kg initial dose regimen will be allowable if deemed appropriate. Doses will be selfadministered or administered at a treatment facility. Duration of treatment for BEs will be at the discretion of the investigator.

Reportable adverse events as defined by EUHASS, including allergic events, treatment-emergent adverse events, transfusiontransmitted infections, inhibitor development, thrombosis and cardiovascular events, malignancies, neurologic events, and death will be reported prospectively. Additionally, all serious adverse events will be collected. All data will be entered into electronic case report forms in ATHN's data management system. with persistent positive titers after 12 weeks. She was refractory to multiple anticoagulants alone (enoxaparin, fondaparinux, apixaban, rivaroxaban, and warfarin), with antiplatelet (aspirin and clopidogrel) and adjunctive therapies (hydroxychloroquine, immunosuppression with steroids and rituximab, and plasmapheresis). Despite these she continued to develop recurrent thrombosis of subclavian, femoral, common femoral, iliac, popliteal and saphenous veins. She additionally developed hepatic infarction and pulmonary embolism along with failure to decrease titers after 6 weeks of plasma exchange. Following this event, eculizumab (600 mg weekly × 4 weeks followed by 900 mg every 2 weeks) was initiated in combination with fondaparinux, aspirin, clopidogrel and hydroxychloroquine. She has remained on this regimen without recurrence of thrombosis from 10/05/19 through 10/29/20 (Table 1) . 

To date, data on 41 bleeds in 14 patients with Type 1 (21%), Type 2 (50%), or Type 3 (29%) VWD have been abstracted; 50% of patients were female, mean ( ± SD) age was 54.8 (21.4) years, 9 patients (64%) had a history of prior GI bleeding. 89% of patients had ≥1 recorded GI-specific morbidity, with confirmed or suspected arterio-venous malformations (AVM) reported as the most common GI-specific morbidity (37%). 71% of patients were on prophylactic VWF concentrate with pdVWF-FVIII at the initial presentation of a bleed. On-demand treatment for GI bleeding included aminocaproic acid, tranexamic acid, pdVWF-FVIII concentrates, rFVIII, rVWF, corticosteroids, polypectomy, and thalidomide; no patients received DDAVP. Across 41 bleeds, 49% were treated with VWF concentrates and at least one non-VWF treatment (including a rFVIII treatment), 41% were treated with VWF concentrates, and 10% with non-VWF treatments only. Median time to resolution of GI bleeding was 9.0 days (range, 2-40). Background: VWD diagnosis is challenging requiring multiple VWF activity tests using many individual assays. We have developed an ELISA-based VWF Multiplex Activity Assay (VWF-MAA) (Roberts JC, et al. Blood 2016) * to address this concern; however, the ability of the VWF-MAA to discriminate between low VWF/type 1 VWD, variant VWD, and normal subjects has not been evaluated.

To evaluate the VWF-MAA and its ability to differentiate between low VWF/type 1 VWD, variant VWD, and normal subjects in individuals undergoing an initial laboratory evaluation for bleeding. (VWF propeptide). Samples were compared to 30% standard control plasma by a ratio of each unique VWF activity over VWF:Ag as previously described. Data were compared to the Versiti (VBRI) research laboratory and the local Center (LC) assigned diagnosis.

VWF:Ag ratio of <1.7 was considered "low VWF/type 1 VWD" as this approximates <51 U/dL when compared to 30% control plasma where control ratio is 1. 2 were erroneously assigned type 2A due to low VWF:CB3 OD ratio, 2 missed type 2B assignment due to lack of VWF:GPIbM enhanced OD ratio, and 2 missed type 2M/2M-C due to normal VWF:GPIbM ratio and low VWF:Ag ratio.

We demonstrate that the VWF-MAA has utility in differentiating low VWF/type 1 VWD, variant VWD, and normal subjects in individuals undergoing an initial laboratory evaluation for bleeding. Our evaluation comparing multiple hemostasis laboratory data highlight the challenges associated with current VWD diagnosis. . Payors have expressed concerns regarding these rising costs, warning they may have to resort to actions such as limit CF options, higher cost tiers, and dispensed drug limits. Helping payors understand how CF is dispensed, when and why it is infused, will mitigate these concerns. Logging apps exist but their use varies. While important to clinical practice, infusion logs can also improve CF assay management. A novel passive infusion logging system (PILS) may help increase the number of patients using them.

Objectives: Describe real-time clotting factor assay management with a PILS and measure ease of use and overall satisfaction. the pharmacy entered the prescription and dispensation information in the system and affixed an associated patient-specific label to each vial box, and (2) during the PI, PBDs scanned the label(s) with an associated smartphone app which instantly logged the infusion's date, time and dose, and removed it from the home inventory; breakthrough bleeds were recorded the same way plus a few extra steps describing the reason for the infusion. Surveys to assess attitudes with logging, PILS ease of use, and PBD/pharmacy satisfaction were sent at baseline, 2-week, 3 and 6 months.

Of the 36 PBD who took the baseline survey, 30 (83.3%) completed the 2-week and 26 (72.2%) the 3 and 6-month surveys; 14 pharmacy staff took 1 survey. Before using PILS, 18 PBD (50%) used paper logs, 15 (41.7%) an app, 5 (13.9%) did not log, 2 (5.6%) had their own spreadsheet, and 1 (2.8%) reported to the pharmacy; 41.9% were extremely/very satisfied with their system and 61.3% said they would recommend it to others. All questions were responded on a 1-5 Likert-type scale where 1 = lowest/worse and 5 = highest/best score. PBDs' overall satisfaction mean was > 4 and did not significantly change over time (p = 0.75); the pharmacy's was 3.57. PBDs agreed that the app was easy to use (M = 4.5) and record an active bleed (M = 4.4). See Table 1 for PBD/pharmacy staff attitudes towards PILS. PBDs were grouped by those who had and didn't have a logging system before PILS, attitudes towards logging were compared -see Table 2 . 

The study aimed to establish the value of specialized telegenetic counseling (TGC) in delivering sensitive genotyping results to women who had undergone MLOF testing by: describing TGC as a way to access to GCs, determining if TGC causes incremental knowledge, if it has an impact on participant's management and plan of care (POC), and its overall satisfaction.

The National Hemophilia Foundation funded the study and, with HTCs, facilitated advertisement for recruiting. It included women enrolled in MLOF who received results but no formal GC session. Using randomization, 2 groups were created. Group 1 (G1) took a baseline survey, received TGC, and completed surveys 3 and 6 months after. Group 2 (G2, control) took a baseline, 3, and 6 month surveys, and then received TGC. The women and GC completed a satisfaction survey after TGC which was done through the HIPPA compliant Zoom platform. An individualized report was sent to every woman at the end of the study.

Results: Data was collected from 2/2018 to 7/2019. All self-referred women (N = 25) were screened: 9 were not eligible and 4 did not finish; 12 completed the study. One non-carrier was excluded from the analysis to improve homogeneity. The sample (n = 11) included 6 women in G1 and 5 in G2. All who completed the baseline survey testing knowledge (n = 10) received perfect scores. At baseline, 1 in each group did not answer questions about a POC; 3 of the remaining 5 in G1 and 1 of the remaining 4 in G2 had a POC -differences were not statistically significant (p = 0.206). By the 6-month survey, 1 in G1 and 2 in G2 acknowledged having a POC. Satisfaction with TGC was positive with 9/11 (81.8%) extremely satisfied, 1 (9.1%) neutral, and 1 (9.1%) somewhat dissatisfied. See Figure 1 for average scores. Nine (81.8%) were very and 2 (18.2%) were somewhat comfortable seeing the counselor on video. Groups differed significantly when asked if they would use TGC again (p = 0.015); all in G1 strongly agreed and, in G2, 1 (20%) strongly agreed, 1 (20%) somewhat agreed, 2 (40%) were neutral, and 1 (20%) strongly disagreed. See Figure 2 for satisfaction mean scores for telemedicine as a modality for TGC.

: Although a small sample, results suggest that TGC may provide a good model to increase access to specialized GCs for PWH seen in HTCs without such specialty. Because all baseline questions were answered correctly, knowledge increment could not be assessed. The impact of TGC on management and POC was not significant. However, both women and GC's expressed great satisfaction with the experience. FORMA-04 was a Phase 3 PK/efficacy/safety study of patients <12 yrs. All PK analyses were performed examining fibrinogen levels at multiple time points after a single 70 mg/kg HFC infusion.

Hemostatic efficacy was assessed for each BE and surgery by an Independent Data Adjudication Committee (IDMEAC) using objective 4-point scales; treatment success defined as an excellent/good rating. Safety was assessed by monitoring adverse events (AEs). Table 2 . Hemostatic efficacy was assessed for 24 patients (89 BEs) and 9 patients (12 surgeries) in those ≥12 yrs, and 8 patients (10 BEs) and 3 patients (3 surgeries) in those <12 yrs. For BE treatment, the IDMEAC rated HFC as successful in 98.9% of patients ≥12 yrs; 100% in patients <12 yrs. For surgical prophylaxis, HFC was rated as 100% successful in both age groups. In patients ≥12 yrs, 5 AEs were reported as possibly related to HFC treatment (drug eruption (2), pyrexia, phlebitis and thrombosis). In patients <12 yrs, 2 AEs were reported as possibly related to HFC; pyrexia and portal vein thrombosis following splenectomy for spontaneous spleen rupture. No deaths or severe/serious allergic reactions were reported. Conclusions: Satisfactory PK profiles of HFC were observed for both adult/adolescent patients and pediatric patients. Numerical differences for e.g. AUC and IVR between age groups were as expected for this type of therapeutic agent. HFC efficacy was comparable between the two age groups for both BE treatment and prophylaxis of perioperative bleeding, and so was the safety data. Background: Ischemic stroke occurs in 700,000 people yearly in the U.S., often resulting in long-term disability. Tissue plasminogen activator (tPA) is able to effect thrombus dissolution and recanalization of occluded vessels, and is the only FDA approved treatment for ischemic stroke. However, it carries a significant risk for secondary hemorrhage. Catheter-based thrombectomy can be effective, but cannot access small vessels and has its own risks. Therefore, additional options are needed to enhance treatment and reduce the associated risks, especially in small vessel thrombi which account for ~20% of ischemic strokes. We have previously shown that colloidal microparticles assembled into microwheels (uwheels) and functionalized with tPA, can assemble, rotate, and translate under the control of applied magnetic fields. These uwheels enable rapid thrombolysis of fibrin gels in microfluidic models of thrombosis. The zebrafish is a vertebrate that is characterized by rapid, external, and transparent development, and is essentially a living microfluidic model. The highly conserved coagulation system enables studies of hemostasis and thrombosis in the context of intact vasculature, coagulation factors, and blood cells.

Objectives: Introduce tPA functionalized uwheels into zebrafish to determine whether they can perform targeted recanalization in vivo.

We used laser-mediated endothelial injury in the posterior cardinal vein (PCV) of 3 day old larvae, which results in rapid formation of an occlusive thrombus, followed by observation for recanalization. Infusion of tPA-coated particles were performed without and with a magnetic field ("tPA-particles" and "tPA-uwheels," respectively).

The length of time for spontaneous recanalization after induced PCV thrombus formation was first established, which did not occur within 4 hours of observation, nor with infusion of saline or uncoated particles. Infusion of tPA alone resulted in lysis within 189.5 ± 70.6 minutes (n = 40), and was 232.2 ± 31.3 minutes (n = 16) for tPA-particles without application of the magnetic field. When a magnetic field was applied to particles or tPA-particles, only tPAuwheels were able to recanalize, in 11.8 ± 5.4 minutes (n = 15). tPA has been shown to have other roles in addition to plasminogen activation. In order to confirm the underlying mechanism, we evaluated tPA-uwheels in plasminogen (plg) knockout fish. We found that using tPA-uwheels, 90% of plg-/-mutants (n = 20) were unable to be recanalized, but conversely 94% and 86% of wild-type (n = 18) and heterozygous (n = 43) siblings, respectively, recanalized within 30 minutes.

Our data show that magnetically powered uwheels as a targeted tPA delivery system are dramatically more efficient at effecting plasmin-mediated thrombolysis than systemic delivery.

Further development of this system in fish and mammalian in vivo models could eventually enable a less invasive strategy for alleviating ischemia that is safer than directed thrombectomy or systemic infusion of tPA. BEs (excluding menstrual bleeds) over 6 months, with ≥2 of these treated with a VWF-containing product, or must have switched to prophylactic treatment with a VWF-containing product within the past 2 years and their prior ODT bleeding history recorded. The ODT will be assessed as part of a run-in observational study (WIL-29) on bleeding profile prior to prophylaxis. Ten pediatric patients aged 6

to 16 years will have baseline PK profiles characterized for VWF (using ristocetin co-factor activity [VWF:RCo]) and FVIII, based on blood samples taken pre-and post-dosing. Prophylactic treatment with VWF/FVIII concentrate for 12 months will be initiated at study start or following PK. Patients will record all BEs to calculate BE frequency and annualized bleeding rate. Treatment efficacy will be assessed by the patient (and investigator in case of on-site treatment) using a 4-point scale. VWF/FVIII concentrate efficacy will be assessed at the end of surgery by the surgeon, post-operatively by the hematologist, with an overall post-operative efficacy assessment by the investigator.

Results: In July 2020, enrollment in the WIL-29 lead ODT study was completed with 55 patients enrolled at 15 sites; Bulgaria, Croatia, Hungary, Russia, Ukraine and the USA. The first patient rolled over into the WIL-31 prophylactic study in June 2020 and 14 patients are currently enrolled. Study end is expected Q2 2021.

bleeding disorders is widely accepted as standard of care to prevent bleeding and preserve patient QoL, there is very little data addressing long-term VWD prophylaxis. WIL-31 will provide data on prophylactic treatment efficacy in reducing bleeding rates, QoL impact of prophylaxis, joint status and menstrual bleed severity in VWD patients. (Goldenberg N, et al. Haematologica 2010) . Surgery is a risk factor for developing HA-VTE in pediatric patients with as many as 43% of patients developing HA-VTE after undergoing surgery. Variables with p-value ≤0.10 in unadjusted models were included in adjusted analysis for further evaluation. The final model was derived using backward selection with significance level of 0.05. Results: 70 providers from 149 HTCs completed the survey. Thus, the response rate was 47% (95% CI 39% to 55%) and 68% (n = 48) of respondents were pediatric hematologists. Results showed that clinicians use EHLs for a variety of indications in persons with severe and non-severe hemophilia. About 48% of respondents had used EHLs in previously untreated patients (PUPs). Majority of respondents, ~94% (n = 66) for persons with hemophilia A (PWHA) and ~84% (n = 59) for persons with hemophilia B (PWHB), preferred to use the same EHL product for acute bleeding in PWH on prophylaxis with EHLs ( Figure 1 ). More number of providers (~66%, n = 46) had used EHLs for acute bleeding in persons with moderate hemophilia than in mild hemophilia (~23%, n = 16). More number of providers (58.5%, n = 41) were willing to switch PWHB than PWHA (20%, n = 14) to EHLs for prophylaxis. For major surgery, > 80% of providers preferred to use SHL over EHLs in PWHA and PWHB (Figure 2 ).

Our study informs about the perception of efficacy of EHLs in PWH among hemophilia treaters in the United States.

Clinicians are comfortable with using EHLs in PWH including PUPs.

The use of EHLs for acute bleeding varies based on severity of hemophilia. Most clinicians did not have concerns with the efficacy of EHLs in controlling acute bleeding in PWH. Clinicians have a higher comfort level with factor IX EHLs for prophylaxis in PWH. Most providers preferred SHLs over EHLs for major surgery. Overall, this study did not identify major concerns about the efficacy of EHLs in managing bleeding diatheses in PWH. is also asking questions that have not been asked before, therefore providing the community with vital data points necessary to help move the future of IBD forward.

Objectives: Increase the understanding of the lived experience, engaging external researchers, monitor how social trends impact the population, and monitor patterns and changes longitudinally.

Recognize and accept the value in the patient's feedback, acknowledge the ability of patients/caregivers to provide input in clinical trial design before the study is developed, integrate the design of patientcentric procedures and schedules, design patient -centric study designs, and overcoming internal barriers to patient engagement.

Longitudinal surveys, virtual advisory panels, embedded educational resources and rapid research cycles.

Results: On October 8th, 2020 there were a total of 795 participants enrolled in CVR; 535 (67%) reported having a bleeding disorder and 260 (33%) reported being a caregiver of a person with a bleeding disorder. When asked about their sex at birth: 416 (52.3%) females and 379 (47.7%) males, however when asked about gender identity the numbers changed slightly to 413 (51.9%) participants who identify as females and 376 (47.3%) who identify as males and 6 other; composed of 4 (0.5%) participants whom identified as transgender and 2 (0.3%) whom selected "I prefer not to answer"

The more participants enrolled in CVR the stronger the data and the community. CVR will establish an audience to draw in for opportunities to participate in patient-reported outcome research and other efforts as well as providing the opportunity to educate and inform individuals and families in the bleeding disorders community (Figure 1, Figure 2 

We have previously demonstrated that a single dose of etranacogene dezaparvovec provides sustained FIX activity into the mild-to normal range for up to 52 weeks post-dose in participants with severe or moderate-severe hemophilia B. Here, two years of follow-up data will be presented.

A Phase 2b, open-label, single-dose, single-arm, multicenter trial (NCT03489291) in adult hemophilia B subjects who were not excluded based on neutralizing antibodies to AAV5. All subjects received a single intravenous dose of etranacogene dezaparvovec (2 × 10e13 gc/kg) and are being followed for 5-years. The primary endpoint was FIX activity at Week 6. Secondary endpoints include e-diary recordings of bleeds and FIX concentrate use, laboratory parameters, joint health, patient reported outcomes, and adverse events (AEs).

All participants had FIX ≤1% (severe or moderatelysevere FIX deficiency), required routine FIX prophylaxis, and had neutralizing activity to AAV5 at baseline. Following AMT-061 treatment, FIX activity increased rapidly to a mean of 31% at Week 6. At Week 52, mean FIX activity increased further to 41% with FIX activity levels of 50%, 31% and 41% in participants 1-3 respectively. There was no relationship between response to etranacogene dezaparvovec and the presence of anti-AAV5

NAbs. As of 52 weeks, there were no bleeds post-treatment and no requirement for FIX replacement aside from protocol specified use for perioperative management in participant 3. There were no clinically significant elevations in liver enzymes and no participants required steroids related to the treatment. One participant experienced 2 mild AEs possibly related to treatment shortly after dosing (self-limiting headache and slightly elevated CRP).

Participant 3 had hip surgery due to worsening of pre-existing avascular necrosis (deemed unrelated to treatment by the investigator) and received FIX per protocol according to standard clinical practice. No participant developed inhibitors to FIX. Updated results to 2 years of follow-up will be presented. (Table 1) , easily extracted from the electronic medical record (EMR), that are available at admission and updated daily. The model has excellent discriminatory capability, with a c-statistic of 0.907 in the derivation cohort and 0.904 in the validation cohort.

To more broadly assess the utility of this model in identifying high risk pediatric inpatients, we developed the following pragmatic trial that has been approved by the Vanderbilt University Medical Center Institutional Review Board. Objectives: This study is designed to assess the efficacy of using a novel risk prediction model with targeted intervention to improve outcomes of hospitalized pediatric patients at high risk for HA-VTE through a randomized, pragmatic trial. Figure 1 displays an overview of the study scheme. All patients admitted to Monroe Carell Jr. Children's Hospital at Vanderbilt who are 21 years of age and younger will be included in the study. The automated EMR-based prediction model described above will be used to calculate an HA-VTE risk prediction score on all patients. Patients randomized to the intervention arm will have their score displayed to the HA-VTE research team, comprised of hematologists, who will review the clinical situation and make recommendations regarding prophylactic interventions, including anticoagulation, to the admitting team. The risk prediction scores of patients randomized to the control arm will not be displayed to the research team. Both groups will continue to receive current standard of care. The primary endpoint of the study is the frequency of HA-VTE events per arm, and secondary endpoints include the number of patients in the intervention arm who receive anticoagulation and the number of bleeding-related adverse events.

The pragmatic trial is underway. We anticipate approximately 20,000 eligible patient admissions during one year of the study, with 10,000 patients expected to be in the intervention arm.

We report a novel study design to evaluate efficacy of a HA-VTE predictive model in a general pediatric inpatient population.

Multiple aspects of the trial occur in an automated fashion, which provides faster access to data, increased ease of use, and potential applicability across various medical centers. We anticipate that data from this trial will improve identification of pediatric patients at high risk for HA-VTE development across the country.

Other: N/A. 

Background: Gene therapy aims to provide long-term therapeutic benefit from a single administration. AMT-060 is an adenoassociated virus serotype 5 (AAV5) vector with a codon-optimized wildtype human factor IX (FIX) gene and liver-specific promoter and is being evaluated in 10 participants with severe/moderate-severe hemophilia B over 5 years (Phase 1/2 study, NCT02396342).

Objectives: To describe efficacy and safety outcomes from an analysis up to 5-years post-AMT-060.

Adult males with FIX activity ≤2% and a severe bleeding phenotype received a single intravenous infusion of AMT-060 (5 × 10 12 gc/kg, Cohort 1, n = 5) or (2 × 10 13 gc/kg, Cohort 2, n = 5).

Assessments include FIX activity, FIX replacement use, annualized bleeding rate (ABR), treatment-related adverse events (TRAE), immunological and inflammatory biomarkers up to 5 years (Cohort 1) and 4.5 years (Cohort 2). (Cohort 1) and 100% (Cohort 2). Eight of 9 participants using prophylaxis at baseline were able to discontinue. No participants developed FIX inhibitors or signs of sustained AAV5 capsid-specific T-cell activation. As previously reported, TRAE were mainly reported in the first 3.5 months after treatment, including three participants who experienced transient mild elevations in alanine aminotransferase.

One additional TRAE (joint swelling post-exercise) was observed during the last 12 months of observation post-treatment. Updated data, up to 5-years of observation, will be presented. Objectives: To design and implement a national research agenda that embraces patient-centric principles and holistically addresses the priorities of the IBD community, particularly among under-represented populations. This is being informed through community listening activities and solicitation of input into the critical areas that can achieve dramatic improvements for the community today and in the future.

Methods: Virtual community listening sessions were conducted with diverse groups representing adults with IBDs, caregivers, patient organizations, chapter directors, healthcare providers, and industry representatives. These discussions will be supplemented by a survey developed by and administered through the National Hemophilia Foundation's (NHFs) chapters as well as information gathered through NHF's community powered registry, Community

Voices in Research. These insights will be distilled into core themes, informing action by a steering committee and expert working groups as part of a State of the Science (SOS) Research Summit in 2021 culminating in a research roadmap designed and endorsed by the entire IBD community and championed by community research leaders.

In total, 78 individuals participated in 9 listening sessions:

31% with an IBD, 5% caregivers, 51% healthcare professionals and 35% chapter leaders (Table 1) Conclusions: Actively soliciting the community's views is central in our process to advance research in IBDs. At the end of the SOS process, with input from patients and families, we will have a roadmap that will positively impact and ring true to the voices heard during this planning process.

Other: Thanks to Kellie Hotz, K. Hotz Consulting Inc., for assistance with medical writing.

HTRS.O1.1, HTRS.O1

HTRS.P1.7, HTRS.P2.5, HTRS

HTRS.O1.1, HTRS.P1.1

HTRS.P1.1, HTRS

HTRS.O2.1, HTRS.O2

HTRS.P2.5, HTRS

HTRS.O4.1, HTRS.O4

HTRS.O1.1, HTRS.O1

HTRS.O2.1, HTRS.O2